Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Manzoor · SciRah

Researcher profile · Semantic Scholar

B. Manzoor

Share profile

B. Manzoor — researcher profile on SciRah

h-index: 13
Works: 60
Citations: 667

Most-cited papers

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
O. Al-Sawaf, S. Robrecht, Can Zhang, S. Olivieri +24 more
2024Blood140 citations Open access
Semantic Scholar
Real‐World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation
B. Manzoor, Todd A. Lee, L. Sharp, S. Walton +2 more
2017Pharmacotherapy81 citations
Semantic Scholar
Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review
W.-H. Cheng, B. Manzoor, L. Cavallari, L. Sharp +4 more
2014The Annals of Pharmacotherapy74 citations Open access
Semantic Scholar
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C. Thompson, R. Harrup, Catherine C. Coombs, L. Roeker +34 more
2022Blood Advances53 citations Open access
Semantic Scholar
Comparative Effectiveness of Patient-centered Strategies to Improve FDA Medication Guides
M. Wolf, S. Bailey, M. Serper, Meredith F. Smith +6 more
2014Medical Care40 citations
Semantic Scholar
Drug-Alcohol Interactions Among Older Adults in the United States
D. Qato, B. Manzoor, Todd A Lee
2015Journal of The American Geriatrics Society39 citations Open access
Semantic Scholar
High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy
B. Manzoor, S. Walton, L. Sharp, W. Galanter +2 more
2017Journal of Thrombosis and Thrombolysis27 citations
Semantic Scholar
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner‐City Population
Y. Lee, B. Manzoor, L. Cavallari, E. Nutescu
2018Pharmacotherapy26 citations
Semantic Scholar
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
M. Shadman, B. Manzoor, K. Sail, H. Tuncer +27 more
2023Clinical Lymphoma, Myeloma & Leukemia20 citations Open access
Semantic Scholar
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
A. Chatterjee, S. Shapouri, B. Manzoor, A. Ravelo +4 more
2021Journal of Managed Care & Specialty Pharmacy18 citations Open access
Semantic Scholar
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
S. K. Cho, B. Manzoor, K. Sail, H. Parise +7 more
2020PharmacoEconomics (Auckland)18 citations Open access
Semantic Scholar
Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment
A. Ravelo, K. Myers, Robyn Brumble, Cooper Bussberg +4 more
2024Future Oncology14 citations Open access
Semantic Scholar
Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
Meghan C. Thompson, J. Allan, K. Sail, B. Manzoor +22 more
202014 citations Open access
Semantic Scholar
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
A. Chatterjee, G. van de Wetering, R. Goeree, C. Owen +4 more
2022PharmacoEconomics - Open12 citations Open access
Semantic Scholar
Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
Nilanjan Ghosh, B. Manzoor, B. Fakhri, N. Emechebe +4 more
2024British Journal of Haematology9 citations Open access
Semantic Scholar
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
M. Davids, A. Chatterjee, A. Ravelo, S. Shapouri +4 more
2019Blood9 citations Open access
Semantic Scholar
Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study
Nilanjan Ghosh, T. Eyre, Jennifer R. Brown, N. Lamanna +29 more
2024American journal of hematology/oncology8 citations Open access
Semantic Scholar
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
Scott F. Huntington, B. Manzoor, D. Jawaid, J. Puckett +4 more
2024Journal of Managed Care & Specialty Pharmacy8 citations Open access
Semantic Scholar
Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study
N. Ghosh, N. Lamanna, T. Eyre, Catherine C. Coombs +26 more
2023Blood8 citations Open access
Semantic Scholar
Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI
L. Roeker, J. Burke, Joanna M. Rhodes, N. Emechebe +9 more
2025Cancers7 citations Open access
Semantic Scholar
Outcomes of systematic anticoagulation management in pharmacist and nurse specialized clinics
B. Manzoor, J. Bauman, N. Shapiro, T. Stamos +2 more
2018Journal of the American College of Clinical Pharmacy7 citations
Semantic Scholar
P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY
F. Lansigan, T. Eyre, N. Ghosh, B. Manzoor +25 more
2023HemaSphere4 citations Open access
Semantic Scholar
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia
S. Huntington, B. Manzoor, J. Puckett, Sachin Kamal-Bahl +4 more
2023Leukemia and Lymphoma4 citations Open access
Semantic Scholar
The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences
M. Davids, B. Manzoor, Nisha C. Hazra, Honghao Fang +6 more
2022Journal of Clinical Pathways4 citations Open access
Semantic Scholar
Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting
B. Manzoor, Scott F. Huntington, D. Jawaid, J. Puckett +4 more
2023Blood3 citations Open access
Semantic Scholar
Patient Preferences for Fixed Versus Treat-to-Progression Therapies in Chronic Lymphocytic Leukemia
A. Ravelo, K. Myers, C. Ervin, Robyn Brumble +5 more
2023Blood3 citations Open access
Semantic Scholar
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
A. Mato, K. Sail, M. Yazdy, B. Hill +26 more
2019Blood3 citations
Semantic Scholar
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting
B. Fakhri, N. Emechebe, B. Manzoor, D. Jawaid +3 more
2024JCO Oncology Practice2 citations Open access
Semantic Scholar
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia
Scott F Huntington, Joanna M. Rhodes, B. Manzoor, D. Jawaid +6 more
2024JCO Oncology Practice2 citations Open access
Semantic Scholar
Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study
N. Lamanna, Jennifer R. Brown, C. Ujjani, T. Eyre +30 more
2024Blood2 citations
Semantic Scholar
Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments
A. Ravelo, K. Myers, Robyn Brumble, Cooper Bussberg +4 more
2022Blood2 citations Open access
Semantic Scholar
Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France
H. Fang, H. Ravonimbola, Nisha C. Hazra, Zhou Zhou +5 more
2020Blood2 citations Open access
Semantic Scholar
Real-world overall survival and time to next treatment among elderly United States Medicare beneficiaries with chronic lymphocytic leukemia in the front-line setting
Scott Huntington, J. Puckett, B. Manzoor, N. Emechebe +5 more
2025Blood1 citations
Semantic Scholar
Venetoclax retreatment of real-world patients with chronic lymphocytic leukemia previously treated with venetoclax-based regimens
M. Shadman, Meghan C. Thompson, N. Ghosh, N. Emechebe +7 more
2025Blood1 citations
Semantic Scholar
The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab
K. Guinan, K. Mathurin, Jean Lachaine, Nancy Paul Roc +6 more
2024Cancers1 citations Open access
Semantic Scholar
PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
J. Allan, A. Skarbnik, N. Emechebe, H. Alhasani +1 more
2022HemaSphere1 citations Open access
Semantic Scholar
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada
A. Chatterjee, G. van de Wetering, R. Goeree, A. Desbois +4 more
20201 citations Open access
Semantic Scholar
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
M. Shadman, K. Sail, B. Manzoor, M. Yazdy +29 more
2019Blood1 citations Open access
Semantic Scholar
Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia
I. Fleury, Brian T. Hill, T. Eyre, C. Ujjani +29 more
2026Blood neoplasia0 citations Open access
Semantic Scholar
EE251 COST-SAVINGS ASSOCIATED WITH VENETOCLAX-OBINUTUZUMAB VERSUS COVALENT BRUTON’S TYROSINE KINASE INHIBITOR IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD STUDY
A. Skarbnik, N. Emechebe, B. Fakhri, Samin Houshyar +6 more
2026Value in Health0 citations
Semantic Scholar
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting
Scott F Huntington, J. Puckett, B. Manzoor, N. Emechebe +5 more
2026Cancers0 citations Open access
Semantic Scholar
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis
G. van de Wetering, Carolyn Owen, V. Banerji, A. Gosselin +7 more
2025PharmacoEconomics - Open0 citations Open access
Semantic Scholar
EE436 Real World Healthcare Resource Utilization (HRU) and Costs Associated With Mantle Cell Lymphoma (MCL) Therapies in the Frontline (1L) and Relapsed/Refractory (R/R) Setting
Nilanjan Ghosh, D. Jawaid, N. Emechebe, B. Manzoor +1 more
2025Value in Health0 citations Open access
Semantic Scholar
EE355 Healthcare Resource Utilization in the Management of Patients with Relapse/Refractory Mantle Cell Lymphoma in Canada
K. Guinan, M. Ham, Harpreet Singh, Nancy Paul Roc +6 more
2025Value in Health0 citations Open access
Semantic Scholar
HSD51 Premature Treatment Discontinuation Among Previously Untreated Medicare Beneficiaries With Chronic Lymphocytic Leukemia Treated With Oral Targeted Therapies: A Real-World Analysis
Scott F Huntington, J. Puckett, D. Jawaid, B. Manzoor +5 more
2025Value in Health0 citations Open access
Semantic Scholar
EE93 Estimated Total Cost of Care (TCC) of First-Line (1L) Fixed-Duration BCL2i versus Treat-To-Progression BTKi Regimens in Patients with Chronic Lymphocytic Leukemia (CLL) in the United States (US): A Population-Based Model
Sophia S Li, K. Rosettie, B. Manzoor, F. El-Moustaid
2025Value in Health0 citations Open access
Semantic Scholar
Estimated total cost of care and patient out-of-pocket cost savings with first-line fixed duration venetoclax + obinutuzumab compared with treat-to-progression BTKi regimens among Medicare-eligible patients with chronic lymphocytic leukemia in the United States following the Inflation Reduction Act.
Sophia Li, K. Rosettie, B. Manzoor, Carolina Reyes +1 more
2025Blood0 citations
Semantic Scholar
Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience
C. Jensen, M. Shadman, A. Chang, N. Lamanna +29 more
2025Blood0 citations
Semantic Scholar
Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)
Scott F Huntington, D. Jawaid, Steven E Marx, J. Puckett +7 more
2024Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
H. Tuncer, Nilanjan Ghosh, I. Fleury, L. Leslie +31 more
2024Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Emechebe×20
Invite
N. Emechebe — researcher profile on SciRah
D. Jawaid×16
Invite
D. Jawaid — researcher profile on SciRah
M. Shadman×13
Invite
M. Shadman — researcher profile on SciRah
L. Roeker×12
Invite
L. Roeker — researcher profile on SciRah

×12

Invite

A. Ravelo — researcher profile on SciRah

Invite

K. Sail — researcher profile on SciRah

Invite

T. Eyre — researcher profile on SciRah

Invite

H. Tuncer — researcher profile on SciRah

Invite

C. Ujjani — researcher profile on SciRah

Invite

I. Pivneva — researcher profile on SciRah

Invite

P. Barr — researcher profile on SciRah

Invite

A. Skarbnik — researcher profile on SciRah